FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website



Please select your country. This will keep you up to date with your country-specific information.

Breast Cancer is a challenge best faced together

One in eight women in Europe will develop breast cancer at some stage in her life. Yet closer cooperation between specialists, new diagnostics and therapies have improved survival rates significantly1,2 as well as Patients’ quality of life.3-5 

Sysmex is playing a significant role in these improvements for you as a clinician, and your patients.

  • Eliminate concerns regarding guidewire or radioactive makers for impalpable lesion localisation by using the Sentimag® / Magseed® system for true convenience for you and your patients.
  • Your patients can benefit from tissue-saving operations and fewer long-term effects thanks to the sentinel lymph node biopsy (SNLB) concept.
  • You no longer need radioactive markers to detect sentinel lymph nodes as the Sentimag® / Sienna+® system detects them magnetically.
  • Get reliable findings based on whole nodes – not just slices – using OSNA’s molecular lymph node analysis; also inter-operatively. It’s shown to help deliver individualised therapy decisions too.
  • Reduce your patients’ limitations in everyday life using modern breast cancer management even with the most essential, systemic cancer treatment.


  1. SEER Stat Fact Sheets: Female Breast Cancer. (accessed Sep. 20, 2016).
  2. Allemani C. et al. (2015): Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887
    patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 385:977-1010.
  3. Kirshbaum M.N. et al. (2016): Open access follow-up care for early breast cancer: a randomised controlled quality of life analysis. Eur. J. Cancer Care, advance online publication, doi: 10.1111/ecc.12577.
  4. Hamer J. et al. (2016): Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer, advance online publication, doi:10.1007/s00520-016-3417-6.
  5. Pinto A.C. et al.(2011): Improving quality of life after breast cancer: dealing with symptoms. Maturitas, 70(4):343-348.


Endomag®, Sentimag®, Magseed® and Sienna+® are registered European Community Trademarks of Endomagnetics Ltd.

Oncology Report - New Customer Magazine

Watch Penny’s story
Watch video
Watch video
Enjoy our Media Centre
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Company movie